News Article - April 17, 2025 Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
News Article - February 25, 2025 Monument Therapeutics Secures £850k to Advance Breakthrough Schizophrenia Treatment
News Article - January 21, 2025 Monument Therapeutics Announces Grant of Chinese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
News Article - January 14, 2025 Monument Therapeutics Announces Grant of Japanese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
Press Release - November 26, 2024 Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Press Release - November 19, 2024 Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Press Release - October 15, 2024 Monument Therapeutics Secures £1M Investment To Fund Its Schizophrenia Programme And Drive Next Stage of Growth
Press Release - September 17, 2024 Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980
Press Release - April 18, 2024 Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.
Press Release - January 4, 2024 Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Press Release - March 28, 2023 Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference
Press Release - January 9, 2023 Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Press Release - August 2, 2022 Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Press Release - June 13, 2022 Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
News Article - May 2, 2022 Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
News Article - April 26, 2022 Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!
News Article - April 11, 2022 Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA
Press Release - March 15, 2022 Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference
Press Release - March 15, 2022 Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference
Press Release - December 14, 2021 Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
Press Release - September 21, 2021 Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study
Press Release - August 12, 2021 Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board
Press Release - August 3, 2021 Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director
Press Release - July 1, 2021 Digital brain biomarker company Monument Therapeutics raises £2.6 million
